Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment

Clinical Oncology

Volumn 27, Issue 7, 2015, Pages 394-400

  Ramsden, K ^a   Laskin, J ^a   Ho, C ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Adjuvant; Dose intensity; Dose reduction; Predictors; Resected NSCLC; Time to adjuvant chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; ANTINEOPLASTIC AGENT; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; CLINICAL TRIAL; DRUG DOSE REDUCTION; FEMALE; HUMAN; HUMAN TISSUE; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PATIENT REFERRAL; PRIORITY JOURNAL; SYSTEMIC THERAPY; TIME TO TREATMENT; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DOSE RESPONSE; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; PLATINUM COMPOUNDS; PNEUMONECTOMY; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME-TO-TREATMENT; VINBLASTINE;

EID: 84930486249     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2015.03.001     Document Type: Article

References (20)

1. Anonymous Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J 1995, 311:899-909.
2. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. NEngl J Med 2004, 350:351-360. The International Adjuvant Lung Cancer Trial Collaborative Group.
3. Winton T., Livingston R., Johnson D., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. NEngl J Med 2005, 352:2589-2597.
4. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant navelbine international trialist association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
5. Scagliotti G.V., Fossati R., Torri V., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. JNatl Cancer Inst 2003, 95:1453-1461.
6. Waller D., Peake M.D., Stephens R.J., et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the big lung trial. Eur J Cardiothorac Surg 2004, 26:173-182.
7. Strauss G.M., Herndon J.E., Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups. JClin Oncol 2008, 26:5043-5051.
8. Pignon J.P., Tribodet H., Scagliotti G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. JClin Oncol 2008, 26:3552-3559.
9. Booth C.M., Shepherd F.A., Peng Y., et al. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada. JThorac Oncol 2012, 7:559-566.
10. Booth C.M., Shepherd F.A., Peng Y., et al. Time to adjuvant chemotherapy and survival in non-small cell lung cancer: a population-based study. Cancer 2013, 119:1243-1250.
11. Lohrisch C., Paltiel C., Gelmon K., et al. Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. JClin Oncol 2006, 24:4888-4894.
12. Gagliato Dde M., Gonzalez-Angulo A.M., Lei X., et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. JClin Oncol 2014, 32:735-744.
13. Biagi J.J., Raphael M.J., Mackillop W.J., et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011, 305:2335-2342.
14. Murakami Y., Uemura K., Sudo T., et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol 2013, 71:419-429.
15. Rodriguez K.A., Guitron J., Hanseman D.J., et al. Adjuvant chemotherapy and age-related biases in non-small cell lung cancer. Ann Thorac Surg 2012, 94:1810-1814.
16. Tinker A.V., Speers C., Barnett J., et al. Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers. Ecancermedicalscience 2008, 2:63.
17. Smoragiewicz M., Javaheri K.R., Yin Y., et al. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. JGastrointest Cancer 2014 Dec, 45(4):460-465. 10.1007/s12029-014-9639-2.
18. Griffin D.A., Penprase B., Klamerus J.F. Relative dose intensity - improving treatment and outcomes in early-stage breast cancer: a retrospective study. Oncol Nurs Forum 2012, 39:E459-E467.
19. Sandy J., Della-Fiorentina S. Relative dose intensity in early stage breast cancer chemotherapy: a retrospective analysis of incidence, risk factors and outcomes at a south-west Sydney cancer clinic. Asia Pac J Clin Oncol 2013, 9:365-372.
20. Chang W.J., Sun J.M., Lee J.Y., et al. Aretrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Lung Cancer 2014, 84:51-55.